eduKateSG · Why Science?
Follow a device study after approval
Use FDA Post-Approval Study records through PMA links, study objectives, protocols, populations, enrollment, follow-up, progress reports, status definitions, final reports and program boundaries.
Premarket approval answers an important question, but it does not always answer every question for the rest of a device’s life. FDA can require a Post-Approval Study as a condition of approval to gather additional information after a device enters wider or longer use.
The PAS database links a device and PMA application with the study objective, protocol features, progress and FDA assessment. This gives students a visible route from an approval condition to later evidence.
Did you know? A PAS is different from a Section 522 postmarket-surveillance study. Both can examine device performance after marketing, but they arise under different authorities and use different record systems.
This guide supports regulatory study literacy and does not recommend a device or interpret care for an individual patient.
Chapter index
Chapters 1–9: PMA identity, requirement, objective and design
- 1. A PAS is tied to a PMA approval condition
- 2. The PMA number anchors the regulatory decision
- 3. The study identifier anchors follow-up
- 4. The objective defines the remaining question
- 5. Protocol design controls inference
- 6. Population boundaries matter
- 7. Sample size is a plan and a result
- 8. Follow-up duration reveals delayed outcomes
- 9. Enrollment status is operational evidence
Chapters 10–17: enrollment, follow-up, status and final assessment
- 10. Progress reports create a timeline
- 11. Study status needs its official definition
- 12. Interim results are not final conclusions
- 13. Final reports close the evidence loop
- 14. PAS differs from Section 522 surveillance
- 15. PAS differs from MAUDE reports
- 16. Results can affect labeling or further action
- 17. PAS literacy supports evidence careers
CHAPTER 1 OF 17 · Connect approval and study
1. A PAS is tied to a PMA approval condition
A post-approval study becomes useful when the PMA, requirement, protocol and FDA assessment stay connected. FDA may require a post-approval study as a condition of approving a PMA or PMA supplement when additional information is needed after marketing. This helps readers follow evidence after approval without assuming that a study requirement proves a defect.
Try this
Evidence question: Which record field or official document supports the point about a pas is tied to a pma approval condition? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for a pas is tied to a pma approval condition. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for a pas is tied to a pma approval condition, its identifier or version context, and one limit that must remain visible.
CHAPTER 2 OF 17 · Connect approval and study
2. The PMA number anchors the regulatory decision
Some questions remain after approval because longer follow-up or broader clinical use is needed. The PAS record links back to the PMA database so readers can connect the study requirement with the approval order, device, indication and decision date. It also separates PAS obligations from Section 522 surveillance and spontaneous reports.
Try this
Evidence question: Which record field or official document supports the point about the pma number anchors the regulatory decision? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for the pma number anchors the regulatory decision. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for the pma number anchors the regulatory decision, its identifier or version context, and one limit that must remain visible.
CHAPTER 3 OF 17 · Connect approval and study
3. The study identifier anchors follow-up
The PAS database turns a condition of approval into a public timeline of study progress. A PAS number or database study record distinguishes one requirement from other studies conducted for the same device or application. The application and study identifiers make the route repeatable.
Try this
Evidence question: Which record field or official document supports the point about the study identifier anchors follow-up? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for the study identifier anchors follow-up. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for the study identifier anchors follow-up, its identifier or version context, and one limit that must remain visible.
CHAPTER 4 OF 17 · Connect approval and study
4. The objective defines the remaining question
Status labels need the study objective, dates and FDA comments around them. The study objective states what FDA expects the manufacturer to learn, such as longer-term safety, effectiveness, device durability or performance in a defined population. Clinical conclusions still depend on design, follow-up and current labeling.
Try this
Evidence question: Which record field or official document supports the point about the objective defines the remaining question? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for the objective defines the remaining question. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for the objective defines the remaining question, its identifier or version context, and one limit that must remain visible.
A post-approval study becomes useful when the PMA, requirement, protocol and FDA assessment stay connected. Prospective cohorts, registries, retrospective analyses and other designs differ in comparison groups, bias, data completeness and causal strength. This helps readers follow evidence after approval without assuming that a study requirement proves a defect.
Try this
Evidence question: Which record field or official document supports the point about protocol design controls inference? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for protocol design controls inference. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for protocol design controls inference, its identifier or version context, and one limit that must remain visible.
Some questions remain after approval because longer follow-up or broader clinical use is needed. Age, diagnosis, indication, implant status, device version and enrollment setting define the group to which study findings most directly apply. It also separates PAS obligations from Section 522 surveillance and spontaneous reports.
Try this
Evidence question: Which record field or official document supports the point about population boundaries matter? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for population boundaries matter. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for population boundaries matter, its identifier or version context, and one limit that must remain visible.
The PAS database turns a condition of approval into a public timeline of study progress. Planned sample size, actual enrollment, attrition and analyzable population can differ; each number answers a different question. The application and study identifiers make the route repeatable.
Try this
Evidence question: Which record field or official document supports the point about sample size is a plan and a result? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for sample size is a plan and a result. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for sample size is a plan and a result, its identifier or version context, and one limit that must remain visible.
Status labels need the study objective, dates and FDA comments around them. Some device questions require years of observation, making visit schedules, loss to follow-up and censoring central to interpretation. Clinical conclusions still depend on design, follow-up and current labeling.
Try this
Evidence question: Which record field or official document supports the point about follow-up duration reveals delayed outcomes? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for follow-up duration reveals delayed outcomes. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for follow-up duration reveals delayed outcomes, its identifier or version context, and one limit that must remain visible.
A post-approval study becomes useful when the PMA, requirement, protocol and FDA assessment stay connected. Recruiting, ongoing, complete or delayed status describes study conduct, not the direction or strength of final results. This helps readers follow evidence after approval without assuming that a study requirement proves a defect.
Try this
Evidence question: Which record field or official document supports the point about enrollment status is operational evidence? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for enrollment status is operational evidence. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for enrollment status is operational evidence, its identifier or version context, and one limit that must remain visible.
Some questions remain after approval because longer follow-up or broader clinical use is needed. Manufacturers submit periodic reports and FDA records assessments of milestones, deficiencies and recommended actions as applicable. It also separates PAS obligations from Section 522 surveillance and spontaneous reports.
Try this
Evidence question: Which record field or official document supports the point about progress reports create a timeline? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for progress reports create a timeline. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for progress reports create a timeline, its identifier or version context, and one limit that must remain visible.
The PAS database turns a condition of approval into a public timeline of study progress. Labels such as progressing adequately, progress inadequate or completed should be interpreted through FDA program definitions and the dated record. The application and study identifiers make the route repeatable.
Try this
Evidence question: Which record field or official document supports the point about study status needs its official definition? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for study status needs its official definition. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for study status needs its official definition, its identifier or version context, and one limit that must remain visible.
Status labels need the study objective, dates and FDA comments around them. Early observations may be incomplete, underpowered or affected by ongoing follow-up and should not be presented as a final study finding. Clinical conclusions still depend on design, follow-up and current labeling.
Try this
Evidence question: Which record field or official document supports the point about interim results are not final conclusions? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for interim results are not final conclusions. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for interim results are not final conclusions, its identifier or version context, and one limit that must remain visible.
CHAPTER 13 OF 17 · Interpret final evidence
13. Final reports close the evidence loop
A post-approval study becomes useful when the PMA, requirement, protocol and FDA assessment stay connected. A final report and FDA review connect completed methods, results, limitations and regulatory conclusions; enrollment completion alone is insufficient. This helps readers follow evidence after approval without assuming that a study requirement proves a defect.
Try this
Evidence question: Which record field or official document supports the point about final reports close the evidence loop? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for final reports close the evidence loop. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for final reports close the evidence loop, its identifier or version context, and one limit that must remain visible.
CHAPTER 14 OF 17 · Interpret final evidence
14. PAS differs from Section 522 surveillance
Some questions remain after approval because longer follow-up or broader clinical use is needed. Both are postmarket study programs, but their legal authority, triggering decision, identifiers and databases differ. It also separates PAS obligations from Section 522 surveillance and spontaneous reports.
Try this
Evidence question: Which record field or official document supports the point about pas differs from section 522 surveillance? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for pas differs from section 522 surveillance. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for pas differs from section 522 surveillance, its identifier or version context, and one limit that must remain visible.
The PAS database turns a condition of approval into a public timeline of study progress. A planned study uses a protocol and denominator, while MAUDE contains reports with substantial reporting and rate limitations. The application and study identifiers make the route repeatable.
Try this
Evidence question: Which record field or official document supports the point about pas differs from maude reports? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for pas differs from maude reports. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for pas differs from maude reports, its identifier or version context, and one limit that must remain visible.
CHAPTER 16 OF 17 · Interpret final evidence
16. Results can affect labeling or further action
Status labels need the study objective, dates and FDA comments around them. Post-approval evidence can inform labeling, communications, additional study, regulatory action or the understanding of benefits and risks. Clinical conclusions still depend on design, follow-up and current labeling.
Try this
Evidence question: Which record field or official document supports the point about results can affect labeling or further action? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for results can affect labeling or further action. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for results can affect labeling or further action, its identifier or version context, and one limit that must remain visible.
CHAPTER 17 OF 17 · Interpret final evidence
17. PAS literacy supports evidence careers
A post-approval study becomes useful when the PMA, requirement, protocol and FDA assessment stay connected. Epidemiologists, statisticians, clinicians, engineers and regulators use PAS records to follow a question from approval condition to study conclusion. This helps readers follow evidence after approval without assuming that a study requirement proves a defect.
Try this
Evidence question: Which record field or official document supports the point about pas literacy supports evidence careers? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for pas literacy supports evidence careers. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for pas literacy supports evidence careers, its identifier or version context, and one limit that must remain visible.
Contents · Previous chapter · Continue at the Science Learning Hub
A post-approval claim is strongest when the approval condition and study evidence stay linked
The PAS record turns continuing oversight into a traceable research timeline. It helps learners distinguish protocol, progress, interim observation and final FDA assessment.
Save the PMA and supplement numbers, PAS identifier, device and applicant, study objective, design, population, sample size, comparison group, endpoints, follow-up, enrollment and report dates, status, FDA assessment, final result and access date.
| Reading object | What it can support | Question to keep visible |
|---|---|---|
| PMA link | Approval and condition that created the requirement | Which device and indication? |
| PAS objective | Question the required study must address | Which population and endpoint? |
| Study status | Dated FDA assessment of progress | Which definition applies? |
| Final report | Completed methods, results and limitations | What conclusion did FDA record? |
Sources and next reading
Substantive resource claims in this article were checked against the primary pages below. A structured record is a route into evidence; it does not by itself prove a scientific conclusion. Recheck the live record, evidence labels and release context before using it in assessed work or research.
For a classroom enquiry, save a short research receipt containing the question, search terms, selected object, exact identifier, version, access date and the evidence boundary you observed. Add the file or page that supports each statement. This small routine turns browsing into accountable science learning and gives a teacher, classmate or future analyst a route they can independently follow.
Before sharing the conclusion, ask another reader to retrace the route without verbal hints. If they reach a different version, file or interpretation, improve the receipt and narrow the claim. Reproducibility begins with this practical check. It teaches careful reading, supports fair collaboration and keeps uncertainty visible while evidence moves from an online service into notes, analysis and a final explanation.
A useful final review separates five questions. What object was found? Which organisation or repository maintains it? What exact evidence was inspected? Which statement does that evidence support? What remains uncertain? Answer each question in one sentence, then connect every answer to a visible field, file or source page. This review catches common mistakes: citing a collection when a file supplied the value, treating the newest release as the analysed release, confusing permission with scientific suitability, or turning a discovery count into a conclusion. It also gives students a calm way to improve work. A missing detail becomes a next research step instead of an invitation to guess. When the route is complete, the final explanation can stay simple because the identifiers, dates, versions, limitations and supporting evidence are already organised underneath it.
Primary sources
- FDA Post-Approval Studies Database — accessed 25 October 2026.
- Post-Approval Studies Program — accessed 25 October 2026.
- FDA Medical Device Databases — accessed 25 October 2026.
- FDA PMA Database — accessed 25 October 2026.
- Postmarket Requirements for Devices — accessed 25 October 2026.